[go: up one dir, main page]

CY1114310T1 - Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου - Google Patents

Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου

Info

Publication number
CY1114310T1
CY1114310T1 CY20131100756T CY131100756T CY1114310T1 CY 1114310 T1 CY1114310 T1 CY 1114310T1 CY 20131100756 T CY20131100756 T CY 20131100756T CY 131100756 T CY131100756 T CY 131100756T CY 1114310 T1 CY1114310 T1 CY 1114310T1
Authority
CY
Cyprus
Prior art keywords
compositions
immunosuppressive compositions
new glycolipid
glycolipid
new
Prior art date
Application number
CY20131100756T
Other languages
English (en)
Inventor
Paul Joseph Dominowski
Ramasamy Mannar Mannan
Sangita Mediratta
Original Assignee
Zoetis P Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis P Llc filed Critical Zoetis P Llc
Publication of CY1114310T1 publication Critical patent/CY1114310T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αυτή αφορά σε συνθέσεις και μεθόδους παρασκευής σταθερών στοκ διαλυμάτων ανοσοενισχυτικού διαλύτη και τελικές συνθέσεις ανοσοενισχυτικού που περιλαμβάνουν γλυκολιπίδια, ασθενή οξέα, αλκοόλες, μη ιονικά επιφανειοδραστικά και ρυθμιστικά.
CY20131100756T 2006-01-26 2013-09-03 Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου CY1114310T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76227906P 2006-01-26 2006-01-26
US81498406P 2006-06-20 2006-06-20
EP07705530.9A EP1991266B1 (en) 2006-01-26 2007-01-15 Novel glycolipid adjuvant compositions

Publications (1)

Publication Number Publication Date
CY1114310T1 true CY1114310T1 (el) 2016-08-31

Family

ID=38309580

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100756T CY1114310T1 (el) 2006-01-26 2013-09-03 Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου

Country Status (20)

Country Link
US (1) US8460679B2 (el)
EP (2) EP1991266B1 (el)
JP (1) JP5538725B2 (el)
KR (2) KR101202553B1 (el)
AR (1) AR059192A1 (el)
AU (1) AU2007209104B2 (el)
BR (1) BRPI0706709B8 (el)
CA (1) CA2634888C (el)
CY (1) CY1114310T1 (el)
DK (1) DK1991266T3 (el)
ES (1) ES2425576T3 (el)
ME (3) ME00045B (el)
NO (1) NO341463B1 (el)
NZ (1) NZ569375A (el)
PL (1) PL1991266T3 (el)
PT (1) PT1991266E (el)
RS (2) RS20080318A (el)
RU (1) RU2392965C2 (el)
TW (1) TWI372631B (el)
WO (1) WO2007085962A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
ES2728949T3 (es) 2008-06-27 2019-10-29 Zoetis Services Llc Composiciones adyuvantes novedosas
JP5723280B2 (ja) 2008-10-03 2015-05-27 ノヴァルティス アーゲーＮｏｖａｒｔｉｓ Ａｇ ウシヘルペスウイルス１型の組成物、ワクチン及び方法
EP2968376B1 (en) * 2013-03-15 2019-06-05 GlaxoSmithKline Biologicals S.A. Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
US10117921B2 (en) 2013-09-19 2018-11-06 Zoetis Services Llc Oil-based adjuvants
AU2014354967B2 (en) 2013-11-26 2019-04-11 Zoetis Services Llc Compositions for induction of immune response
AU2016206525A1 (en) 2015-01-16 2017-07-13 United States Of America, As Represented By The Secretary Of Agriculture Foot-and-mouth disease vaccine
PT3325015T (pt) * 2015-07-20 2021-07-08 Zoetis Services Llc Composições de adjuvante de lipossoma
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN110713520B (zh) * 2019-11-06 2021-01-01 中国石油天然气股份有限公司 油酰基氨基酸-γ-L-谷氨酰-L-半胱氨酰-甘氨酸多肽及其制备与应用
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
CN121360223A (zh) 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291019A (en) * 1979-07-09 1981-09-22 Iowa State University Research Foundation, Inc. Vaccine for infectious bovine rhinotracheitis
DE3213650A1 (de) 1982-04-14 1983-10-27 Bayer Ag, 5090 Leverkusen N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr
DE3403495A1 (de) 1983-11-23 1985-05-30 Bayer Ag, 5090 Leverkusen Phosphorylierte glycosylamide, -harnstoffe, -carbamate und -thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3346623A1 (de) 1983-12-14 1985-07-04 Bayer Ag, 5090 Leverkusen N-glycosylierte harnstoffe, carbamate und thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
FI109332B (fi) * 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
AU1591402A (en) 2000-10-02 2002-04-15 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
RU2392965C2 (ru) 2010-06-27
RS20080318A (sr) 2009-05-06
EP1991266B1 (en) 2013-06-26
RS52930B (sr) 2014-02-28
HK1128078A1 (en) 2009-10-16
BRPI0706709B8 (pt) 2021-05-25
AR059192A1 (es) 2008-03-12
EP1991266A2 (en) 2008-11-19
US8460679B2 (en) 2013-06-11
ME00045B (me) 2010-10-10
NO341463B1 (no) 2017-11-20
NZ569375A (en) 2010-05-28
TWI372631B (en) 2012-09-21
AU2007209104B2 (en) 2010-04-08
TW200738268A (en) 2007-10-16
NO20083405L (no) 2008-10-23
BRPI0706709B1 (pt) 2021-03-23
BRPI0706709A2 (pt) 2011-04-05
MEP4508A (en) 2010-06-10
PT1991266E (pt) 2013-08-28
AU2007209104A1 (en) 2007-08-02
EP2481423A1 (en) 2012-08-01
KR101202553B1 (ko) 2012-11-20
US20070196384A1 (en) 2007-08-23
WO2007085962A3 (en) 2007-12-27
JP2009524638A (ja) 2009-07-02
RU2008129203A (ru) 2010-03-10
DK1991266T3 (da) 2013-08-26
PL1991266T3 (pl) 2013-11-29
KR20110140140A (ko) 2011-12-30
CA2634888A1 (en) 2007-08-02
JP5538725B2 (ja) 2014-07-02
WO2007085962A2 (en) 2007-08-02
KR20080080223A (ko) 2008-09-02
ME01545B (me) 2014-04-20
ES2425576T3 (es) 2013-10-16
CA2634888C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
CY1114310T1 (el) Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
BR112012019693A2 (pt) anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
MX2007013759A (es) Agentes de union de esclerostina.
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
CL2012000401A1 (es) Metodo para hacer una composicion para producir un recubrimiento ultrahidrofobo que comprende combinar un primer solvente y las particulas las cuales no son solubles pero dispersables en primer solvente y combinar con segundo solvente, obtener composicion y recuperacion de la composicion; recubrimiento ultrahidrofobo; y composicion.
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
BRPI0916884A2 (pt) composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CL2011003113A1 (es) Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica.
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
PA8792401A1 (es) Fenilendiaminas
BRPI0817351A2 (pt) Composição para cuidado pessoal
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
BRPI1013051A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para fazer uma composição imunogênica, e, kit.
CY1112187T1 (el) Αλατα βενζιμιδαζολυλ πυριδυλ αιθερων και φαρμακοτεχνικες μορφες αυτων
UY31012A1 (es) Formas solidas de la oxima de la (e)-1-(4-((1r, 2s, 3r)-1,2,3,4-tetrahidroixibutil)-1h-imidazol-2-il)etanona
NO20073167L (no) Skjaerbeskyttende midler for isolering ved mikrofiltrering